Publication:

Effect of myo-inositol on ovulation induction outcomes in women with polycystic ovary syndrome

Background Polycystic ovarian syndrome (PCOS) is a common endocrine condition affecting reproductive-aged women that is distinguished by insulin resistance, hyperandrogenism, and anovulation. Myo-inositol, an insulin-sensitizing drug, has emerged as a promising complementary therapy for enhancing reproductive outcomes. The study aimed to assess whether myo-inositol supplementation affected ovulation induction outcomes in women with PCOS undergoing reproductive treatments.

Methods This investigation was carried out at Department of Obstetrics and Gynecology, Asgar Ali Medical Hospital, Dhaka, Bangladesh from January 2023 to December 2025. A prospective comparison study included 100 women diagnosed with PCOS based on the Rotterdam criteria. Participants were divided into two groups: the control group (n=50) received standard ovulation induction, and the myo-inositol group (n=50) received 2 grams of myo-inositol twice daily. The primary outcomes were ovulation confirmation and endometrial thickness. The data were entered and analyzed with statistical package for the social sciences (SPSS) version 26.

Results Baseline characteristics were comparable among groups. The myo-inositol group had significantly greater ovulation rates (74.0% versus 56.0%, p=0.04) and endometrial thickness (8.1±1.4 mm versus 7.4±1.3 mm, p=0.01) than the control group. Mid-luteal progesterone levels were higher in the myo-inositol group (10.6±4.1 ng/ml versus 8.9±3.7 ng/ml, p=0.03). Multivariable analysis revealed that myo-inositol supplementation is an independent predictor of ovulation (adjusted OR 2.30, 95% CI 1.01-5.24, p=0.047).

Conclusion Myo-inositol supplementation dramatically improves ovulation rates and endometrial growth in women with PCOS who are undergoing ovulation induction, making it an excellent adjuvant therapy for improving reproductive outcomes in this population.